Matches in Nanopublications for { <http://rdf.disgenet.org/resource/nanopub/NP1040523.RARacMQg961QX-jD6io3wa7LYCG0Tvmd8Q2kE936fyPis130_assertion> ?p ?o ?g. }
Showing items 1 to 6 of
6
with 100 items per page.
- NP1040523.RARacMQg961QX-jD6io3wa7LYCG0Tvmd8Q2kE936fyPis130_assertion type Assertion NP1040523.RARacMQg961QX-jD6io3wa7LYCG0Tvmd8Q2kE936fyPis130_head.
- NP1040523.RARacMQg961QX-jD6io3wa7LYCG0Tvmd8Q2kE936fyPis130_assertion description "[However, there are subgroups of patients with HCV-2, such as those with advanced fibrosis/cirrhosis, in whom SVR rates are still suboptimal, and highly responsive groups in whom SVR rates reach 95%.]. Sentence from MEDLINE/PubMed, a database of the U.S. National Library of Medicine." NP1040523.RARacMQg961QX-jD6io3wa7LYCG0Tvmd8Q2kE936fyPis130_provenance.
- NP1040523.RARacMQg961QX-jD6io3wa7LYCG0Tvmd8Q2kE936fyPis130_assertion evidence source_evidence_literature NP1040523.RARacMQg961QX-jD6io3wa7LYCG0Tvmd8Q2kE936fyPis130_provenance.
- NP1040523.RARacMQg961QX-jD6io3wa7LYCG0Tvmd8Q2kE936fyPis130_assertion SIO_000772 23286844 NP1040523.RARacMQg961QX-jD6io3wa7LYCG0Tvmd8Q2kE936fyPis130_provenance.
- NP1040523.RARacMQg961QX-jD6io3wa7LYCG0Tvmd8Q2kE936fyPis130_assertion wasDerivedFrom befree-2016 NP1040523.RARacMQg961QX-jD6io3wa7LYCG0Tvmd8Q2kE936fyPis130_provenance.
- NP1040523.RARacMQg961QX-jD6io3wa7LYCG0Tvmd8Q2kE936fyPis130_assertion wasGeneratedBy ECO_0000203 NP1040523.RARacMQg961QX-jD6io3wa7LYCG0Tvmd8Q2kE936fyPis130_provenance.